Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03960333 · ClinicalTrials.gov registry record
Immunometabolism in Pediatric Obesity
A clinical trial, sponsored by Arkansas Children's Hospital Research Institute.
- Completed
- Registry status
- 82
- Enrollment target
NCT03960333: Completed study, sponsored by Arkansas Children's Hospital Research Institute.
NCT03960333 is a clinical trial that has completed, run by Arkansas Children's Hospital Research Institute. The registered enrollment target is 82 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03960333 has completed, sponsored by Arkansas Children's Hospital Research Institute.
- COMPLETED
- Registry status
- 82 participants
- Enrollment target
Study Summary
This is a study to learn about obesity and how insulin resistance and Type 2 Diabetes develops in children.
Primary Outcome
We will measure and report the percent of ATP derived from glycolysis and oxidative phosphorylation in circulating CD4+ T cells as well as the % CD4+CD25+CD127lowFoxP3+ cells (Tregs) in overweight/obese vs lean children.
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 82 participants |
| Start Date | 2019-04-25 |
| Est. Completion | 2024-06-30 |
What the finished NCT03960333 record still lists
NCT03960333 is an observational study that tracks outcomes without assigning an intervention. The registry caps enrollment at 82 participants, a relatively small participant target.
The record links to 0 conditions, and to 0 interventions.
NCT03960333 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT03960333 about?
NCT03960333 is a clinical study titled "Immunometabolism in Pediatric Obesity". This is a study to learn about obesity and how insulin resistance and Type 2 Diabetes develops in children.
What is the current status of trial NCT03960333?
This trial is currently completed. The enrollment target is 82 participants. The study started on 2019-04-25. Estimated completion is 2024-06-30.
Who is sponsoring clinical trial NCT03960333?
This trial is sponsored by Arkansas Children's Hospital Research Institute, which has 97 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03319901 · 82 participants · Phase 1
Venetoclax and Chemotherapy as Frontline Therapy in Older Patients and Patients With Relapsed/Refractory ALL
- NCT03493425 · 82 participants · Phase 2
Chemotherapy Before Surgery and Radiation Therapy or Surgery and Radiation Therapy Alone in Treating Patients With Nasal and Paranasal Sinus Cancer That Can Be Removed by Surgery
- NCT04105270 · 82 participants · Phase 2
RMT in Combination With Durvalumab + Chemo in Untreated Adenocarcinoma NSCLC. A Randomized Double Blind Phase II Trial
- NCT04428658 · 82 participants · NA
Randomized Trial of Supplemental Synchronous and Asynchronous Telehealth to Improve Glycemic Control for Pediatric Patients With Type 1 Diabetes
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI